FutureMeds Commitment to Vaccine Trials in Europe

As new infections emerge and old ones resurface, Europe’s ageing population makes life-course immunisation more urgent than ever. Here’s how FutureMeds supports vaccine studies through dedicated sites, decentralised and hybrid delivery, and partnerships that embed research into local healthcare systems.

Our world is changing fast. New infectious threats appear. Familiar pathogens return. And across Europe, demographic shifts mean more people are vulnerable to preventable diseases, newborns, pregnant women, older adults, and those living with chronic conditions.

Vaccines remain one of our strongest defences, not only for public health, but for resilient societies and thriving economies. Yet Europe’s share of global vaccine trials is declining. If that trajectory continues, the impact is larger than R&D: reduced access to innovation, weaker integration of research into healthcare systems, and a gradual erosion of local health security.

FutureMeds is working with sponsors, CROs, and healthcare stakeholders to change that trajectory, strengthening Europe’s position as a hub for advanced vaccine research and delivery.

Why Europe’s vaccine trial capability matters

When vaccine research happens close to patients and healthcare systems, it creates compounding benefits:

• Earlier access to innovation for local populations

• Stronger research readiness across care settings

• More representative evidence across diverse communities

• Faster learning loops between clinical practice and development
  

A declining trial footprint risks eroding these advantages at a time when Europe needs greater preparedness and speed.

FutureMeds’ approach to vaccine trials

FutureMeds’ model is designed to help vaccine studies run predictably across countries while keeping the patient experience central. We build upon four pillars.

1) Expanding access with dedicated sites and decentralised delivery

Vaccine trials only succeed when they reach the right participants quickly and retain them.

• Dedicated research sites across Europe enable consistent execution and high-quality data collection across multiple geographies and patient populations.
  

• Hybrid and decentralised elements help reduce participation burden (travel, time off work, caregiver logistics), improving engagement and retention.
  

• Inclusive reach across life stages supports recruitment in populations often underrepresented or harder to access through traditional site-only models.
  

The goal is practical: make participation easier, reduce friction, and keep studies on track.

2) Driving innovation with digital tools and better population insight

Operational excellence matters, but it’s not enough on its own. Vaccine studies increasingly demand smarter matching, better forecasting, and faster decision-making.

That’s why we’re developing and integrating tools that help:

• Match volunteers to studies faster
  

• Improve population insight and feasibility confidence
  

• Reduce avoidable delays through better operational planning and earlier signal detection
  

This is about accelerating timelines without compromising quality by improving how quickly the right patients can be identified, engaged, and supported.

3) Building partnerships that embed research into healthcare

Vaccine confidence and participation are built locally through trusted institutions and credible messengers.

FutureMeds partners with organisations that help guide immunisation decisions, including:

• public health stakeholders,

• local healthcare providers,

• and patient associations.
  

These partnerships strengthen recruitment pathways, improve participant understanding, and support long-term trial readiness, helping research become a more integrated part of local healthcare systems rather than a separate, unfamiliar activity.

4) Supporting life-course immunisation

Life-course immunisation requires infrastructure that can support vaccination research across every stage of life, with consistent execution across countries and care settings.

Our mission is to help make life-course immunisation a reality for every generation by delivering trials that are accessible, patient-centred, and operationally reliable.

Looking ahead: Europe prepared for whatever tomorrow brings

Vaccine trials are more than studies. They are a measure of preparedness—and a lever for strengthening Europe’s health security and competitiveness.

"Immunisation is increasingly a cornerstone of global health security, societal resilience, and economic sustainability. That belief shapes how we partner and how we build delivery models that work in real life. The task is meaningful. The opportunity is enormous. And the progress is real."

- Iwona Tongbhoyai, Chief Client Solutions Officer

If you’re looking to run vaccine trials across Europe with speed, quality, and a patient-first approach FutureMeds is ready to help.